Wuxi AppTec
TOPIC
 / company

Wuxi AppTec

Wuxi AppTec
Wuxi AppTec
Wuxi AppTec is Asia's largest provider of contract pharmaceutical research, helping drug makers shorten their discovery and development procedures. Its platform is used by more than 6,000 customers, including biotech and pharmaceutical companies, research institutions, researchers, scientists and entrepreneurs in more than 30 countries. The company was founded by Ge Li, who also chairs Wuxi Biologics.
Chairman / President
Li Ge
CEO / Managing Director
Chen Minzhang
CFO / Finance Director
Shi Ming
Industry
Biopharmaceutical
Website
wuxiapptec.com
Headquarters address
288 Fute Zhong Road Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, China
Stock Code
SEHK:603259
SSE:603259
Year founded
2000
last updated:
30 September, 2024
WuXi AppTec says it provides US lawmakers and federal agencies with information about the services it provides to customers in the US and around the world. Photo: Shutterstock
Biomedicine: Companies

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

Biomedicine: Policy

Shanghai to back local biopharma firms’ overseas push, regulatory compliance

videocam
Wuxi Biologics

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

US-China relations

Senior US official lauds China cooperation on tech-transfer controls

‘End-use checks’ have improved since the pandemic, but pending congressional legislation is keeping mainland firms in limbo.

videocam
6
Matthew Axelrod (right), US assistant secretary for export enforcement at the Department of Commerce, speaks at the Centre for Strategic and International Studies in Washington on Thursday, with William Reinsch of CSIS.
US-China relations

‘China week’ at US House puts biotech firms, Hong Kong offices in cross hairs

Most of the scheduled 28 items have bipartisan support and follow efforts to tackle national and economic security threats posed by Beijing.

videocam
19
US-China relations

US clinical trials in China draw questions on IP theft, Uygur involvement

American drug companies have collaborated with Chinese military-run hospitals to conduct hundreds of such trials, US lawmakers say.

Advertisement
Advertisement
Hong Kong stock market

Hong Kong stocks slip on weak Chinese corporate earnings

WuXi AppTech, WuXi Biologics and Xpeng weighed on the market as fourth-quarter earnings of Chinese companies trail those of peers in the rest of Asia, according to Goldman Sachs.

Electronic screen showing stock prices outside the Exchange Square in Central, Hong Kong in February 2024. Photo: Xiaomei Chen
US-China relations

Time to ‘cut off’ US outbound investment in China biotech firms: House panel

Bipartisan support on show amid concern ‘every bit of value flowing’ to companies in the industry ‘will be used to strengthen the CCP and the PLA’.

videocam
20
US-China relations

Chinese biotech firm Wuxi should be sanctioned, US lawmakers urge

In a letter dated February 12, the lawmakers told Treasury Secretary Janet Yellen, Defence Secretary Lloyd Austin and Commerce Secretary Gina Raimondo that the global pharmaceutical giant’s links to China’s Communist Party and military threatened US national security.

videocam
9
Hong Kong stock market

Li Auto and WuXi Apptec to join Hong Kong’s Hang Seng Index in December

Chinese electric-car maker Li Auto and pharmaceutical company WuXi Apptec will join the Hang Seng Index as new constituents next month, according to the latest quarterly review by Hong Kong’s index compiler.

The new additions will increase the number of constituents to 82 from 80, says index compiler Hang Seng Indexes. Photo: Reuters
Medicine

AI drug firm Insilico could boost Hong Kong drug discovery sector. Here’s how

Insilico Medicine, a Hong Kong-based artificial intelligence (AI) biotechnology company, hopes to add momentum to the city’s health technology industry with the development of its AI-discovered drug.

videocam
The global AI drug discovery market is expected to grow at a compound annual growth rate of about 34 per cent to US$5.6 billion by 2029 from last year, according to Polaris Market Research. Photo: Shutterstock Images
Medicine

China’s leading biotech research firm focused on US acquisitions

Wuxi AppTec’s executives say they will fully comply with stringent US requirements as they pursue deals in life sciences and biotech.

IPO

With Shanghai listing done, Chinese biotech firm readies Hong Kong IPO

China stock market

Wuxi AppTec tells Chinese investors to go slow as its stock surges

Shares of the medical researcher, which listed in Shanghai this month after delisting from New York in 2015, have surged almost five-fold from its IPO price

Wuxi AppTec is valued at 86.1 times estimated earnings against the 65.4 times average for the industry. Photo: Shutterstock
IPO

China fast tracks biotech firm’s IPO in race as Asia’s fundraising hub

Mainland’s leading biotech firm privatised in New York two years ago, but has been fast-tracked towards the A-share market just seven weeks after applying to list

Wuxi AppTec’s listing is expected to raise more than 5.7 billion yuan (US$907 million), which will be used to expand its research facilities and build new plants. Photo: Shutterstock
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement